What will be the impact on Stryker's market share in the peripheral vascular segment by end of 2025?
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Industry reports and market analysis publications
Stryker to Acquire Inari Medical for $4.9 Billion at $80/Share, Focusing on VTE Treatments
Jan 6, 2025, 09:09 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. This acquisition will allow Stryker to expand its offerings into the high-growth peripheral vascular segment, focusing on venous thromboembolism (VTE) treatments. Inari's innovative product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Less than 10% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Delayed • 25%
Completed • 25%
Modified Terms • 25%
Cancelled • 25%
Yes • 50%
No • 50%
Neutral • 25%
Unchanged • 25%
Negative • 25%
Positive • 25%
Yes • 50%
No • 50%
No new competitors • 25%
3 or more new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more major competitors • 25%
2 major competitors • 25%
1 major competitor • 25%
No major competitors • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
10% to 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy gains market share over Zepbound • 25%
Wegovy maintains current market share • 25%
Zepbound gains >10% market share over Wegovy • 25%
No • 50%
Yes • 50%
3-4 • 25%
None • 25%
5 or more • 25%
1-2 • 25%